An investigation for investors in NASDAQ:AMPH shares concerning possible violations of securities laws by Amphastar Pharmaceuticals and certain of its directors and officers was announced.
Investors who purchased shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) concerning whether certain statements by Amphastar Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Amphastar Pharmaceuticals Inc reported that its its annual Total Revenue rose from $210.46 million in 2014 to $251.52 million in 2015 and that its Net Loss declined from $10.70 million in 2014 to $2.79 million in 2015.
Shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) grew from %11.05 per share in February 2016 to as high as $21.66 per share in November 2016.
On December 27, 2016 Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration (“FDA”) issued a Complete Response Letter (“CRL”) to its wholly-owned subsidiary, Armstrong Pharmaceuticals, Inc., for its New Drug Application for Primatene Mist (epinephrine inhalation aerosol). Amphastar Pharmaceuticals Inc said that the CRL indicated that Armstrong should make further changes to the label and packaging for Primatene Mist and then conduct another Human Factor validation study to assess consumers’ ability to use the product without the guidance of a doctor or pharmacist. Amphastar is evaluating the content of the letter and plans further discussions with the FDA.
Shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) declined on December 28, 2016, to as low as $18.13 per share.
On January 13, 2017, NASDAQ:AMPH shares closed at $17.15 per share.
Those who purchased NASDAQ:AMPH shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com
Leave Your Comments